Srini Pharmaceuticals is an API manufacturer based in India. It holds 11 active US drug master files and 7 valid CEPs across a filed portfolio of 12 molecules. Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 18 October 2019 as NAI. Customs aggregates show $19.4M of exports covering 264 molecules to 29 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Nalgonda, India | 3004015257 |
| Visakhapatnam, India | 3042718107 |
| Choutuppal, India | Not on file |
| Bhongiri, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Labetalol | EDQM, SFDA (Saudi Arabia), US FDA | 3 |
| Amlodipine | SFDA (Saudi Arabia), US FDA | 2 |
| Dextromethorphan | EDQM, US FDA | 2 |
| Esomeprazole | EDQM, US FDA | 2 |
| Hydroxychloroquine | SFDA (Saudi Arabia), US FDA | 2 |
| Levetiracetam | EDQM, US FDA | 2 |
| Omeprazole | EDQM, US FDA | 2 |
| Pregabalin | EDQM, US FDA | 2 |
| Rivaroxaban | EDQM, US FDA | 2 |
| Apixaban | US FDA | 1 |
| Dabigatran Etexilate | US FDA | 1 |
| Levofloxacin | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $3.5M | 9 |
| 2025 | Not reported | $19.4M | 29 |
| 2024 | Not reported | $16.3M | 29 |
| 2023 | Not reported | $11.6M | 30 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Srini Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for free